Asset Dedication LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Asset Dedication LLC’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.81K	Buy	6 +1	+20%	+$302	﹤0.01%	1049
2026 Q1	$1.66K	Hold	5	–	–	﹤0.01%	982
2025 Q4	$1.99K	Hold	5	–	–	﹤0.01%	1008
2025 Q3	$2.28K	Buy	+5	New	+$2.04K	﹤0.01%	1008
2023 Q1	–	Sell	-1	Closed	–	–	946
2022 Q4	$0	Buy	+1	New	+$213	﹤0.01%	989
2021 Q4	–	Sell	-16	Closed	-$3K	–	922
2021 Q3	$3K	Buy	+16	New	+$3K	﹤0.01%	853
2018 Q2	–	Sell	-75	Closed	-$9K	–	612
2018 Q1	$9K	Buy	+75	New	+$9.67K	﹤0.01%	382

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Asset Dedication LLC's ALNY Position: Q2 2026 in Review

Asset Dedication LLC increased its Alnylam Pharmaceuticals (ALNY) stake by 20% in Q2 2026, buying an estimated $302 and bringing the position to 6 shares worth $1.81K. The position accounts for ﹤0.01% of the portfolio, ranked #1049.

Asset Dedication LLC first reported a position in ALNY in Q1 2018 and has held it in 7 quarters since. The position peaked at $9K in Q1 2018. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Asset Dedication LLC held 6 shares of Alnylam Pharmaceuticals worth $1.81K as of Q2 2026.
Asset Dedication LLC bought 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
Alnylam Pharmaceuticals made up ﹤0.01% of Asset Dedication LLC's portfolio in Q2 2026, its #1049 holding.
Asset Dedication LLC first reported a position in Alnylam Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
Asset Dedication LLC's Alnylam Pharmaceuticals position peaked at $9K in Q1 2018.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Asset Dedication LLC's 13F filing for Q2 2026, filed 30 Jul 2026.